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1. Introduction
The worldwide incidence of cutaneous melanoma has steadily increased in fair-skinned in‐
dividuals over recent decades with estimates suggesting a doubling of melanoma incidence
every 10-20 years [1]. Melanoma remains the major cause of skin cancer related deaths [2],
with survival rates averaging less than six months for patients with metastases in visceral
organs [3]. Conventional systemic therapies, including single agent dacarbazine and temo‐
zolamide, produce response rates of less than 10%, and are not proven to improve survival
(reviewed in [4]). Recently, however, the treatment of melanoma has been revolutionized by
therapies targeting the RAF-MEK-ERK mitogen activated protein kinase (MAPK) pathway.
This pathway is constitutively activated in the majority of melanomas via oncogenic muta‐
tions in the BRAF kinase or its upstream regulator, N-RAS [5, 6].
Most BRAF mutations produce a single amino acid substitution of valine by glutamic acid at
amino acid 600 (V600E), and this leads to a 500-fold increase in kinase activity [5, 7]. Target‐
ing this mutant BRAF with the highly specific inhibitors, vemurafenib (PLX4032) and dabra‐
fenib (GSK2118436) has produced response rates above 50% and improved progression-free
survival in patients with BRAF-mutant metastatic melanoma [8-12]. Both BRAF inhibitors
are active against melanoma brain metastases [13, 14] and vemurafenib treatment prolongs
overall survival compared with dacarbazine [11]. Despite the marked initial responses to
BRAF inhibitors, tumor re-growth occurs in most patients with a median progression-free
survival of 5 to 6 months [8, 11, 15].
The U.S Food and Drug Administration (FDA) approved the use of vemurafenib for the
treatment of BRAF-mutant melanoma in 2011, and submissions for the use of dabrafenib in
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the treatment of BRAF-mutant melanoma were made in late 2012. We are now beginning to
understand the complex pathways regulating the response and side-effect profiles of these
targeted inhibitors. The challenge is to define the molecular drivers and pathways of resist‐
ance and response and to translate these molecular findings into rational strategies for clini‐
cal testing and improved therapies. In the following chapter we describe the molecular
mechanisms that contribute to BRAF inhibitor resistance in vitro and in vivo. We also high‐
light the current strategies employed to dissect resistance drivers and explore the future of
targeted therapies in the long-term treatment of melanoma.
2. The BRAF kinase and the MAPK pathway
Aberrant activation of the MAPK pathway is present in over 80% of primary cutaneous mel‐
anomas [16]. MAPK signalling is driven by mutated N-RAS and activating mutations in the
downstream RAS effector, BRAF, in 20% and 60% of melanomas, respectively (Figure 1)
[16]. Of cutaneous melanomas with no mutations in BRAF or N-RAS, many activate MAPK
signalling via oncogenic mutations in the receptor tyrosine kinase, c-Kit [17], activating mu‐
tations in the Rac1 GTPase or inactivating mutations in the N-RAS inhibitor NF1 [18].
Among the BRAF mutations identified in melanoma, over 80% involve a single nucleotide
mutation resulting in the substitution of valine for glutamic acid at amino acid 600. This mu‐
tation is also present in up to 80% of benign, growth-arrested nevi [19], implicating BRAF as
an initiating event that co-operates with additional genetic lesions to promote melanoma.
Over 60 other mutations in BRAF have been described in melanoma; most affect codon 600
(V600E, V600K, V600R and V600D), lie within the kinase domain and show elevated kinase
activity. In particular, alterations affecting codon 600 show 150- (BRAFV600K) to 700-
(BRAFV600D) fold more kinase activity than the wild type BRAF protein [7].
A wealth of preclinical data has demonstrated the critical role of BRAFV600E as an oncogene
in melanoma. The specific silencing of BRAF with short interfering (si)RNA resulted in de‐
creased ERK signalling, diminished proliferation and regression of BRAF mutant melano‐
mas [20-23]. More importantly, class I RAF inhibitors, which target the activated form of
RAF kinases, show remarkable antitumor activity; both vemurafenib and dabrafenib have
shown response rates of 50% in patients with BRAF-mutant melanoma [8-12]. In addition,
the selective inhibition of the BRAF target proteins, MEK1/2, with trametinib (GSK11202212)
improved rates of progression-free and overall survival amongst patients with BRAF mu‐
tant melanoma when compared to dacarbazine [9, 15, 24, 25].
3. Mechanisms of acquired BRAF inhibitor resistance in melanoma
Despite the marked initial responses to single-agent BRAF inhibitors, tumor re-growth oc‐
curs in most patients and 5-20% of individuals fail to respond early during treatment [8, 10,
11, 26]. The acquisition of resistance to targeted therapy is common and resistance has been
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observed with trastuzumab in HER2-amplified breast cancer, imatinib in gastrointestinal
stromal tumors (GISTs) and chronic myelogenous leukemia (CML), epidermal growth factor
receptor (EGFR) inhibitors in lung cancer and hedgehog inhibitors in medulloblastoma [27].
Resistance mechanisms to these drugs are complex but include the acquisition of secondary
mutations in the target oncogene that prevent drug binding, up-regulation of signalling
pathways downstream of the target and the induction of alternate, secondary survival path‐
ways. Defining the mechanisms of melanoma resistance to targeted inhibitors is a high pri‐
ority, as it can guide the selection of appropriate drug combinations and advance the
development of new and improved drugs. This is best demonstrated for imatinib-resistant
leukemias. The identification of secondary Bcr-Abl mutations in these resistant cancers pro‐
moted the development of the potent, next-generation receptor tyrosine kinase inhibitors
dasatanib and nilotinib [28].
Figure 1. MAPK signalling cascade. Activation of the RAS GTPase promotes the kinase activity of the RAF serine/
threonine protein kinases, ARAF, BRAF and CRAF. Activated RAF kinases promote the sequential phosphorylation and
activation of the MEK1/2 and ERK1/2 kinases. The ERK proteins translocate into the nucleus and stimulate the transla‐
tion of proteins and the activities of many transcription factors. This leads to a series of gene expression changes, in‐
cluding elevated CCND1 that promotes cell proliferation and survival. Specific inhibitors to RAF and MEK kinases are
indicated. ARAF, v-raf murine sarcoma 3611 viral oncogene homolog; BRAF, v-raf murine sarcoma viral oncogene B1;
CCND1, cyclin D1; CRAF, v-raf-1 murine leukemia viral oncogene homolog 1; ERK, extracellular signal-regulated kin‐
ase; MEK mitogen-activated protein kinase kinase.
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4. Alterations affecting BRAF
Drug resistance is often associated with the acquisition of so-called gatekeeper mutations in
the target oncogene that prevent drug binding. In a series of detailed reports, deep sequenc‐
ing of melanoma biopsies derived from patients progressing on vemurafenib treatment did
not find any secondary BRAF mutations. Moreover, immunoprecipitated BRAF from ve‐
murafenib-resistant melanomas retained drug sensitivity in an in vitro kinase assay, confirm‐
ing drug-target binding was maintained [29].
4.1. BRAF copy number gain
The amplification and overexpression of BRAFV600E  is  associated with BRAF inhibitor re‐
sistance in melanoma [30] (Figure 2). In a sequencing screen of 20 pairs of patient-match‐
ed  baseline  (before  BRAF  inhibitor  therapy)  and  progressing  (acquired  resistance  to
BRAF  inhibition)  melanoma  tissue,  20%  showed  BRAFV600E  copy-number  gains,  ranging
from  2-  to  14-  fold.  These  copy-number  gains,  which  are  likely  underestimates  due  to
non-tumor cell  contamination,  correlated with increased BRAF protein expression in tu‐
mor  specimens.  Moreover,  preclinical  melanoma cell  models  with  ectopically  expressed
BRAFV600E  confirmed that  cells  overexpressing mutant  BRAF developed resistance to ve‐
murafenib and that this resistance could be overcome by increasing the dose of vemura‐
fenib,  applying  MEK  inhibitors  (AZD6244)  or  concurrently  inhibiting  both  MEK  and
BRAF (Figure 1) [30].
Unlike melanoma cell models [30], BRAF-mutant colorectal cancer cells with amplification
of the BRAF gene (2- to 7- fold) were resistance to the MEK inhibitor AZD6244 [31]. In these
colon cancer cells, the increased expression of mutant BRAF resulted in excess activation of
MEK and ERK, rendering cells unresponsive to MEK inhibition. In the presence of the BRAF
inhibitor, AZ628, however, the abundance of activated MEK was reduced and the allosteric
MEK inhibitor AZD6244 prevented ERK phosphorylation [31]. Thus, the concurrent inhibi‐
tion of MEK and BRAF overcomes resistance mediated by BRAF amplification in both mela‐
noma and colorectal cancers.
Intriguingly, BRAF copy-number gains (3- to 4-fold) were also identified in baseline (drug-
naive) melanoma and colorectal tumor samples. In one such colorectal tumor only 28% of
cells showed BRAF amplification and 10% of these tumor cells had more than 10 copies of
BRAF [30, 31]. These data indicate that cell sensitivity to MEK and BRAF inhibition is likely
to reflect the level of BRAF amplification and resistance may arise from the expansion of a
limited number of cells with pre-existing BRAF gains. This notion is consistent with a recent
study showing that K-RAS mutations conferring resistance to EGFR inhibitors were likely to
be present in a clonal subpopulation of the colorectal tumor cells prior to the initiation of
targeted therapy. These results may explain resistance to RAF inhibitors and other targeted
therapies occurs in a highly reproducible fashion within 5 to 6 months [32].
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4.2. BRAF splicing variants
In other melanomas, resistance to vemurafenib was acquired via the expression of splice
variant isoforms of BRAFV600E. Three of five vemurafenib-resistant clones of the SKMEL-238
melanoma cells expressed a novel 61kDa variant of BRAFV600E. This p61BRAFV600E splice var‐
iant, lacked exons 4-8, a region encoding the RAS binding domain, and was sufficient to ren‐
der MEK activation resistant to vemurafenib (Figure 3). The variant appears to arise from a
splicing defect as no intragenic somatic deletions within the BRAF gene were detected [33].
Figure 2. Mechanisms of resistance to BRAF inhibition. MAPK re-activation, in the presence of RAF inhibitors, can
occur via A. the mutational activation and amplification of RAS, B. the upregulation of RTKs such as PDGFRß and
IGF-1R, C. elevated expression of CRAF, COT or CCND1, D. MEK mutations, or E. the expression and dimerization of
BRAFV600E splice variants, such as p61BRAFV600E. Mutant RAS and upregulated RTKs also activate the PI3K/mTOR sur‐
vival pathway, which is further activated by the loss of PTEN (adapted from [87]). AKT, v-akt murine thymoma viral
oncogene; BRAF, v-raf murine sarcoma viral oncogene B1; CCND1, cyclin D1; CRAF, v-raf-1 murine leukemia viral onco‐
gene homolog 1; ERK, extracellular signal-regulated kinase; COT, mitogen-activated protein kinase kinase kinase 8;
MEK mitogen-activated protein kinase kinase; mTOR, mechanistic target of rapamycin; PI3K, phosphoinositide-3-kin‐
ase PTEN, phosphatase and tensin homolog; RTK, receptor tyrosine kinase.
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Figure 3. Aberrant splicing of BRAFV600E confers RAF inhibitor resistance. Several in frame BRAFV600E splice variants
lacking the RAS binding domain have been detected in vemurafenib-resistant melanoma tumor specimens. The exon
structure of full-length and spice variant forms of BRAF are shown. The location of the activating V600E mutation, the
RAS binding and kinase domains are highlighted (adapted from [33]).
It is known that the amino terminus of BRAF negatively regulates its kinase activity by
masking the carboxy-terminal catalytic domain. Upon binding to activated RAS, the amino-
terminal regulatory domain of RAF proteins unfolds to expose the carboxy terminal sites
that are required for dimerization and full kinase activity. The in-frame deletion in the
p61BRAFV600E variant leads to the constitutive dimerization of BRAF in the absence of acti‐
vated RAS [34]. Dimerization of p61BRAFV600E was shown to be critical for mediating BRAF-
inhibitor resistance, as the R509H dimerization-deficient mutant form of p61BRAFV600E was
sensitive to vemurafenib and monomeric p61BRAFV600E was inhibited by vemurafenib in vi‐
tro. Thus, it has been proposed that binding of vemurafenib to one p61BRAFV600E protomer
elicits an allosteric change in the other, drug-free protomer, thereby decreasing its affinity
for the drug (Figure 4). Four independent BRAF splicing variants were also detected in tu‐
mors derived from six of nineteen patients with acquired resistance to vemurafenib (Figure
3). In each case, the alternative splice variants were in frame, lacked the RAS binding do‐
main and were confined to the mutant allele [33]. This indicates that BRAF missplicing is
likely due to a mutation or epigenetic change that specifically impacts the BRAFV600E allele.
Importantly, no splice BRAF variants were detected in 27 melanomas resected from vemura‐
fenib-naive patients [33].
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Figure 4. BRAF dimerization, RAF inhibitor binding and MAPK signalling. Mutant BRAF functions as a monomer
and is effectively inhibited at low RAF inhibitor concentrations. In cells with activated RAS, the binding of RAS to RAF
kinases promotes the homo- and heterodimerization (not shown) of wild type RAF proteins. In the presence of low
BRAF inhibitor concentrations, one protomer of the RAF dimer binds inhibitor and this promotes the transactivation of
the second, inhibitor-free RAF protomer. Thus in RAS-activated cells, BRAF inhibitor can induce the activation of RAF
dimers and promote elevated MAPK signalling. Similarly, dimers of p61BRAFV600E splicing variant are resistant to BRAF
inhibition because binding of the drug to one protomer, allosterically alters the second protomer and diminishes its
affinity for the RAF inhibitor. Much higher concentrations of RAF inhibitor are required to bind both protomers in a
RAF dimer and inhibit ERK signalling.
5. N-RAS mutations
In the normal physiological setting, activated RAS signalling promotes the dimerization and
activation of RAF proteins. In the presence of BRAF inhibitors and RAS signalling, the bind‐
ing of drug to one molecule in a non-mutated RAF dimer can promote activation of the sec‐
ond RAF molecule (Figure 4). Thus, in the presence of RAS activation, the activity of homo-
and heterodimeric RAF complexes can be paradoxically activated by RAF inhibitors [35-37].
In melanomas with BRAFV600E,  any alterations promoting RAF dimerization are predicted
to confer resistance to RAF inhibitors. As expected, activating N-RAS mutations mediate
resistance to vemurafenib [29] and dabrafenib [38]. Oncogenic N-RASQ61K was detected in
a single vemurafenib-resistant clone derived from the M249 melanoma cells.  This resist‐
ant subclone maintained ERK activation in the presence of vemurafenib, presumably via
a kinase switch from BRAF to CRAF (Figure 1) [39, 40]. These cells were also sensitive to
inhibition with the MEK inhibitor,  AZD6244 in the presence or absence of vemurafenib,
suggesting that  in  this  cell  clone oncogenic  N-RAS confers  resistance by principally  en‐
gaging the MAPK cascade.  Oncogenic N-RAS mutations were also detected in a patient
with  acquired  resistance  to  vemurafenib;  separate  N-RAS  mutations  (Q61K  and  Q61R)
were detected in two melanoma biopsies taken on initial progression and six months af‐
ter  initial  progression.  Both  mutations  were  associated  with  copy-number  amplification
and N-RAS overexpression [29].
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In a second study, oncogenic N-RASQ61H was detected in two of six dabrafenib resistant sub-
clones, generated from the MelRMu cell line. In contrast to the initial report [29], these two
N-RAS mutant, MelRMu sublines showed diminished sensitivity to MEK inhibitor, trameti‐
nib and to the combined inhibition of BRAF and MEK, when compared to the parental cells.
Moreover, ectopic expression of N-RASQ61K in the MelRMu cells diminished the efficacy of
combined MEK and BRAF inhibition [38]. A third report also identified N-RAS mutations
(N-RASQ61K and N-RASA146T) in two melanoma sublines with acquired resistance to dabrafe‐
nib. These mutations were shown to confer dabrafenib resistance, and induced the heterodi‐
merization of BRAFV600E with C-RAF in the presence of drug [41]. These N-RAS mutant
clones showed partial sensitivity to trametinib and to the concurrent inhibition of BRAF and
MEK proteins [41]. It is known that mutant N-RAS can signal via multiple pathways includ‐
ing the PI3K/AKT/mTOR survival cascade [42] and consequently, N-RAS mutant dabrafe‐
nib-resistant melanoma cells were responsive to the simultaneous inhibition of MEK and the
PI3K/mTOR pathway [41].
There are some discrepancies in the literature regarding the role of activated RAS in selec‐
tively sensitizing cancer cells to MEK inhibition. Certainly, N-RAS mutation status did not
predict MEK inhibitor sensitivity in melanoma cell lines [43], and MEK inhibitors show only
modest clinical activity in patients with RAS-mutant tumors [9, 44]. It seems likely that the
impact of mutant N-RAS on MEK inhibitor responses reflects its expression and activity and
ultimately the network of activated N-RAS-dependent effectors. This is in agreement with a
recent report demonstrating that K-RAS13D-mutant HCT116 colorectal cancer cells became
resistant to MEK inhibition upon amplification of the driving K-RAS13D oncogene [45].
6. CRAF overexpression
Increased expression of the CRAF kinase has also been associated with BRAF inhibitor re‐
sistance (Figure 2). Villanueva et al. (2010) observed increased CRAF protein levels in mela‐
noma cells chronically treated with the BRAF inhibitor SB-590885. In this cell model MAPK
signalling driven by persistent insulin growth factor receptor (IGF-1R) activity, was rewired
to utilise both CRAF and ARAF (Figure 1), and the inhibition of all three RAF isoforms was
required to inhibit the proliferation of these 885-resistant cells [46]. This is in contrast to mel‐
anoma sublines rendered resistant to the pan-RAF inhibitor AZ628. These AZ628-resistant
cells showed elevated basal levels of CRAF protein, but the knockdown of CRAF alone
strongly inhibited cell proliferation, in the absence of AZ628 treatment [47]. These cells
switched from BRAF to CRAF dependence, and the precise mechanism of CRAF-mediated
AZ628 resistance remains unclear, as this inhibitor strongly suppresses both BRAFV600E and
CRAF [48]. The role of CRAF in conferring RAF-inhibitor resistance may reflect the distinct
genetic profiles of the melanoma cells used, the pathway rewiring involved in resistance, the
mechanism of drug action and its impact on the RAF protein dimerization.
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7. MEK mutations
Mutations in mitogen activated protein kinase, MEK1 have also been shown to confer resist‐
ance to MAPK inhibitors. A random mutagenesis screen of MEK1 revealed that mutations
interfering with target-drug binding (e.g. I99T, G128D, L215P) and mutations that upregu‐
late MEK1 intrinsic activity (e.g. Q56P, P124S) conferred resistance to the allosteric MEK in‐
hibitor AZD6244 [49]. The G128D MEK1 mutation also conferred resistance to the BRAF
inhibitor PLX4720 [50] (Figure 5).
Figure 5.  MEK1 mutations  associated with MAPK inhibitor  resistance.  Allosteric  MEK inhibitors  binds  to  the
MEK1 hydrophobic  pocket  that  includes  residues  from helix  C  and the activation loop.  Primary  MEK1 mutations
affect  this  drug-binding pocket  (e.g.  I99T,  I111N/S,  L115P/R,  G128D,  F129L,  V211D and L215P)  and can directly
perturb  the  allosteric  binding of  the  MEK inhibitor.  Secondary  MEK1 mutations  reside  outside  the  drug-binding
region and include mutations near the amino terminus (e.g. Q56P) and proximal to the helix C (C121S, P124S/L).
These  secondary  MEK1  mutations  increase  MEK1  kinase  activity.  The  C121S  and  P124L  MEK1  mutation  have
been  detected  in  MEK  inhibitor  resistant  patient  tumors  [50],  whereas  P124S  and  I111S  MEK1  mutations  were
identified  in  pre-treatment  melanomas  [54].  Shi  et  al.  found  that  of  the  P124S,  I111S  and  C121S,  only  C121S
conferred vemurafenib resistance in melanoma cells.
Deep sequencing of tumors from five patients progressing on AZD6244 treatment, identified
the MEK1P124L mutation in the progressing, but not pre-treatment tumor sample from one
patient. The existence of this MEK1 mutation was independently verified in ex vivo cell lines
established from tumor material, and its activity in conferring MEK- and BRAF-inhibitor re‐
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sistance validated in transfected melanoma cells. As with BRAF truncation and amplifica‐
tion, alterations in MEK1 protein did not alter the sensitivity of melanoma cells to the
combined inhibition of BRAF and MEK inhibitors. A MEK1C121S mutation was detected via
mutational profiling in a melanoma sample from a patient with acquired resistance to ve‐
murafenib. This mutation was not detected in the pre-treatment biopsy, showed increased
intrinsic kinase activity and conferred resistance to BRAF and MEK inhibition in vitro [50].
BRAFi-resistant YUSIT1 melanoma cells also acquired a MEK1 mutation with increased kin‐
ase activity (K59del). These cells were dependent on MEK1 for proliferation and displayed
higher ERK phosphorylation following treatment with dabrafenib [41].
Resistance to the allosteric MEK inhibitor PD0325901 in breast and colorectal cancer cell
lines was also consistently associated with MEK mutations in the allosteric binding domain.
MEK-inhibitor resistant sublines derived from the MDA-MB-231 breast and HCT-116 colon
cancer cells gained the MEK1L115P and MEK1F129L mutations, respectively and the MEK-inhib‐
itor resistant LoVo colorectal cells acquired a MEK2V215E mutation (homologous to V211D
mutations in MEK1) (Figure 5). The L115P and V211D mutations abrogated MEK inhibitor
binding, while F129L increased the intrinsic activity of MEK and showed enhanced interac‐
tion with CRAF [51, 52]. Cell lines expressing mutant MEK1K57N, which was identified in two
lung adenocarcinomas, also showed decreased sensitivity to MEK inhibition [53].
A  recent  study  found  that  MEK1  mutations  identified  in  resistant  melanoma  lesions
might  not  predict  BRAF-inhibitor  sensitivity.  Shi  et  al  found that  five  of  31  melanomas
excised  pre-BRAF  inhibitor  treatment  carried  concurrent  somatic  BRAF  and  MEK1
(MEK1P124S  and  MEKI111S)  activating  mutations  and  that  three  of  these  five  patients
showed  objective  tumor  responses.  When  the  P124S,  I111S  and  C121S  MEK1  mutants
were  stably  introduced into  a  series  of  melanoma cell  lines,  only  the  MEK1C121S  mutant
restored p-ERK levels  in the presence of  vemurafenib,  even though all  mutants showed
intrinsically enhanced kinase activity [54]  (Figure 5).  Thus,  the relative impact  of  MEK1
mutations may vary depending on the type of mutation, tumor genetic background and
the dependence on BRAF. For instance,  YUSIT1 cells  were dependent on the MEK1K59del
for proliferation,  and the MEK1F129L  mutant may induce a BRAF to CRAF kinase switch
[41, 51]. Finally, a more detailed tumor profile, correlating tumor response with the rela‐
tive  proportion  of  double-BRAF/MEK1 mutant  cells  within  metastases,  will  help  clarify
the precise role of MEK1 in mediating BRAF-inhibitor resistance.
8. COT overexpression
A recent gain of function screen tested the activity of 597 kinases (75% of the annotated hu‐
man kinases) in conferring vemurafenib resistance in the A375 melanoma cell line. Nine can‐
didates, including receptor tyrosine kinases (Axl, ERBB2), conferred significant resistance
with the mitogen activated protein kinase kinase kinase 8 (the gene encoding COT/Tpl2)
emerging as the top candidate. Overexpression of COT resulted in constitutive ERK activa‐
tion in the presence of vemurafenib (Figure 2). COT activated ERK via MEK-dependent and
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-independent mechanisms and ectopic COT expression conferred decreased sensitivity to
the MEK inhibitors CI-1040 and AZD6244. COT expression was also elevated in two of three
patient samples obtained early in the course of treatment and further increased in a relaps‐
ing specimen relative to its pre-treatment and on-treatment controls. Considering that inhib‐
ition of BRAFV600E increases COT expression, it is possible that COT accumulation may
reflect secondary responses to BRAF inhibition and resistance. Nevertheless, the silencing
and inhibition of COT in the RPMI-7951 melanoma cells, which express increased COT, de‐
creased ERK phosphorylation and suppressed cell viability [55].
9. Activation of receptor tyrosine kinases
An emerging theme in BRAF inhibitor resistance is the upregulation and activation of recep‐
tor tyrosine kinases. Garraway and co-workers demonstrated that ectopically expressed re‐
ceptor tyrosine kinases Axl and ERBB2, circumvented vemurafenib activity [55], and two
independent reports detected increased expression and activity of the platelet derived
growth factor (PDGFRß) and IGF-1R in vemurafenib-resistant melanoma sublines [29, 46]
(Figure 2). Vemurafenib-resistant tumor biopsies derived from patients also showed overex‐
pression of PDGFRß (4 of 11 patients) and IGF-1R (2 of 5 patients) compared to the corre‐
sponding pre-treatment tumor specimens [29, 46]. The knockdown or inhibition of PDGFRß
and IGF-1R overcame vemurafenib resistance in cell lines, but resistance was not due to acti‐
vation of ERK alone [29, 46]. Instead, receptor tyrosine kinase-upregulated, vemurafenib re‐
sistant melanoma cell lines, showed phosphorylation of both ERK and PI3K/AKT (Figure 2),
and the concurrent and sustained inhibition of the MAPK and PI3K/AKT/mTOR pathways
was required to overcome PDGFRß- and IGF-1R-mediated vemurafenib resistance [46, 56].
The upregulation and activation of these receptors was not due to gene amplification or ge‐
netic alterations within the coding sequence [29, 46].
These studies predict that RTK activation via increased autocrine tumor cell ligand secre‐
tion, or paracrine ligand production from stromal cells may confer resistance to MAPK in‐
hibition. A recent report found increased activation of the fibroblast growth factor (FGF)
receptor 3 was associated with elevated levels of autocrine secreted FGF2 ligand in vemura‐
fenib resistant melanoma sublines [57]. Moreover the secretion of growth factors from co-
cultured fibroblast cells conferred vemurafenib resistance to BRAF-mutant melanoma cell
lines. Stromal cell secretion of the hepatocyte growth factor (HGF) correlated best with ve‐
murafenib resistance in this cell screen, and HGF was detected in tumor-associated stromal
cells in 23 of 34 melanoma tumors resected from patients prior to MAPK inhibitor treatment.
Critically, these 23 patients also showed activation of the HGF receptor MET in their tumor
biopsies, and had a poorer response to MAPK-inhibitor treatment compared to patients
whose stromal cells lacked HGF expression [58]. Increased plasma HGF levels in 126 meta‐
static melanoma patients, prior to treatment with vemurafenib, was also associated with a
reduction in the progression-free and overall survival rates [59]. The stromal cell secretion of
HGF resulted in reactivation of the MAPK and PI3K/mTOR signalling pathways and imme‐
diate (innate) resistance to RAF inhibition. Whether activation of MET also has a role in ac‐
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quired resistance to RAF inhibitors remains to be determined, but activating somatic MET
mutations and amplifications have been detected in human cancers [60-62]. Regardless, of
the mechanism of MET activation, the sensitivity of MET-activated melanoma cells can be
restored by the simultaneous inhibition of RAF and either HGF or MET [58]. Finally, it is
worth noting that although activation of PDGFRß and IGF-1R are associated with vemurafe‐
nib resistance [29, 46], the ligand activation of these two receptors appears insufficient to
drive sustained pathway activation or vemurafenib resistance [58, 59].
10. Other regulators of response to MAPK inhibitors
Typically, the suppression of MAPK signalling promotes cell cycle arrest that is associated
with increased expression of the CDK inhibitor p27Kip1 and inhibition of cyclin D1 expres‐
sion (Figure 1). Cyclin D1 is a regulator of the cyclin dependent kinases (CDKs) 4 and 6 and
the formation of binary cyclin D-CDK4/6 complexes promote the phosphorylation of the ret‐
inoblastoma protein (pRb) and cell cycle progression [63-65]. Cyclin D1 is commonly ampli‐
fied in melanoma and often in conjunction with mutated BRAF [66, 67]. The clinical
significance of this genotype was demonstrated in BRAF-mutant melanoma cell lines with
increased cyclin D1 protein expression. These cells showed intrinsic resistance to the
growth-arresting effects of the RAF inhibitor, SB590885 and the ectopic expression of cyclin
D1 conferred RAF-inhibitor resistance, which was enhanced by the dual overexpression of
CDK4 and cyclin D1 [67]. These data confirm that the MAPK-independent expression of
critical MAPK downstream targets will regulate RAF-inhibitor response and may diminish
the dependence of cells to oncogenic BRAF.
Several  independent studies have shown that loss of  the phosphatase and tensin homo‐
log (PTEN) tumor suppressor, which occurs in over 10% of melanoma tumors, is predic‐
tive  of  attenuated  RAF-inhibitor  mediated  cytotoxicity  [68,  69].  Cells  lacking  PTEN
remain  dependent  on  MAPK  for  proliferation  but  utilise  increased  AKT  signalling  for
survival  (Figure  2).  Elevated AKT promotes  the  nuclear  exclusion  of  the  FOXO3a tran‐
scription factor, which leads to the downstream suppression of the FOXO3a pro-apoptot‐
ic  target  BIM [69,  70].  Predictably,  ectopic  expression of  activated AKT3 also prevented
BRAF inhibitor  induced BIM and apoptosis  [71]  and MEK inhibitor-sensitive cancer cell
lines  show  significantly  higher  FOXO3a  and  BIM  protein  levels  compared  to  resistant
cell  lines  [70].  Similar  to  RTK-induced  resistance,  the  simultaneous  inhibition  of  the
MAPK and AKT pathways is required to restore PTEN-null cell sensitivity to MAPK in‐
hibitors [68]. Finally, homozygous PTEN loss and increased pAKT levels were associated
with vemurafenib resistance in a progressing biopsy derived from a single patient [46].
Considering the independent roles of cyclin D and PTEN in diminishing dependence on
MAPK signalling and engaging the AKT survival cascade, it  is  anticipated that the con‐
current  alteration  of  these  cell  cycle  regulators  would  confer  increased  levels  of  resist‐
ance  to  MAPK  inhibitors.  In  a  recent  study,  vemurafenib  was  shown  to  have  purely
cytostatic  effects  in  melanoma  cells  with  either  PTEN  or  pRb  loss;  pRb  deleted  cells
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should behave as cells with elevated cyclinD1/CDK4 overexpression. BRAFV600E cells with
concurrent loss of both pRb and PTEN were completely resistant to RAF inhibition, and
these cells continued proliferating in the presence of this RAF inhibitor [68]. The clinical
significance  of  pRb loss  in  conferring  MAPK inhibitor  resistance  is  uncertain,  however,
as pRb loss is uncommon in melanoma [72].
Finally, activation of the STAT3 pathway was found to be associated with AZD6244 resist‐
ance in a panel of lung cancer cell lines. STAT3 activity was shown to decrease BIM accumu‐
lation through the upregulation of miR-17, and the inhibition of STAT3 or miR-17
upregulated BIM and sensitized resistant cells to MEK inhibition [73].
11. Therapies to overcome MAPK inhibitor resistance
Irrespective of the precise mechanisms of resistance to class I RAF inhibitors, tumors that
acquire  resistance  or  are  inherently  insensitive  to  these  inhibitors  often  maintain  some
dependency on the MAPK pathway [29,  33,  38,  55,  57,  74].  These data suggest that fur‐
ther inhibition of the MAPK cascade at the downstream MEK or ERK nodes may be ef‐
fective  in  treating  resistance  to  single  agent  BRAF  inhibitors.  Despite  the  preclinical
evidence of MEK-inhibitor sensitivity in cells with acquired resistance to BRAF inhibitors
[38], clinical trials applying this strategy have been disappointing. The MEK inhibitor tra‐
metinib  showed  minimal  activity  (response  rates  of  3%)  in  patients  previously  treated
with a BRAF inhibitor  [75].  Clinical  benefit  was observed,  however,  when patients  who
progressed on prior BRAF inhibitor were treated with a combination of BRAF and MEK
inhibitors.  Partial  responses  were  observed  in  17%  of  patients,  suggesting  that  dual
MAPK blockade can abrogate some BRAF inhibitor  resistance mechanisms [76].  The tri‐
aging of patients, based on BRAF inhibitor resistance drivers, may also improve the clin‐
ical  benefit  of  second  line  MAPK  inhibitor  therapies.  For  instance,  melanoma  cells
expressing BRAF splice variants are sensitive to MEK inhibition [33],  whereas cells with
BRAF copy number  gains  respond to  the  concurrent  inhibition  of  BRAF and MEK [30,
31].  Finally,  specific  inhibitors  of  ERK have  recently  become available,  and  these  show
anti-proliferative activity in MEK-inhibitor resistant cells and synergise with MEK inhibi‐
tors to prevent or delay the emergence of acquired resistance [52].
Sustained and significant responses have also been observed when RAF-inhibitor resistant
cell lines are treated with combination MAPK and PI3K/mTOR inhibitors. For instance, in
RTK-expressing vemurafenib-resistant cells, inhibition of PI3K/mTOR activity in combina‐
tion with vemurafenib showed potent synergy. Compensatory signalling via MEK permit‐
ted survival in the presence of PI3K/mTOR/MAPK inhibition, but cytotoxicity was restored
using a combination of MEK inhibitor with the dual PI3K/mTOR inhibitor BEZ235 [56]. A
number of combinations of MEK and PI3K/mTOR pathway inhibitors combinations have
entered early phase clinical trials, however their benefit in the setting of BRAF/MEK inhibi‐
tor resistance remains untested.
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Many of  the  proteins  involved  in  melanoma development  and RAF-inhibitor  resistance
are targets of the heat shock protein (Hsp)-90 family of chaperones. Hsp90 proteins regu‐
late  the  conformation,  stability  and  function  of  many  RTKs  and  kinases,  including
IGF-1R, BRAF, CRAF, CDK4, AKT and cyclin D1 [77, 78]. The pharmacological inhibition
of Hsp90 using the selective inhibitor, XL888 abrogated acquired and intrinsic vemurafe‐
nib resistance. XL888 induced apoptosis in melanoma cells with mutant N-RAS, elevated
PDGFRß, COT, IGF-1R, CRAF and cyclin D1. Apoptosis was associated with diminished
accumulation of  the resistance driver,  nuclear accumulation of  FOXO3a and an increase
in  BIM  expression.  Moreover,  Hsp90  inhibition  was  a  more  effective  apoptotic  inducer
when combined with MEK and PI3K inhibition [79]. Hsp90 inhibitors have shown prom‐
ising results in ERBB2-amplified breast cancers [80], but lacked clinical activity in vemur‐
afenib-naive  melanoma  patients  [81].  Evaluation  of  pre-  and  post  treatment  melanoma
biopsies  confirmed  incomplete  degradation  of  BRAFV600E,  when  the  inhibitor  was  given
on a weekly schedule. Whether Hsp90 inhibition will prove effective when administered
more  frequently,  in  RAF-inhibitor  resistant  melanoma  patients,  or  in  combination  with
MAPK inhibitors remains to be tested.
12. Conclusions
BRAF-targeted therapy has recently emerged as the standard treatment for patients with
BRAF-mutant melanoma. Responses are not durable, however and studies of acquired re‐
sistance to BRAF inhibition reveal a diversity of resistance mechanism but a common resist‐
ance theme. Melanoma cells adapt by re-engaging MAPK signalling and activating parallel
survival networks. The management and prevention of BRAF inhibitor resistance is likely to
be achieved through combination therapies. The combination of BRAF and MEK inhibitors
has shown better response than single agent therapy [25] and is currently being evaluated in
phase III clinical trials compared to vemurafenib (NCT01597908) or dabrafenib
(NCT01584648) in treatment naive patients with BRAFV600E mutant melanoma. Trials com‐
bining MEK with AKT inhibitors (NCT01021748), the pan-RAF inhibitor sorafenib and MEK
inhibition (NCT0034999206), testing HDAC inhibition with vorinostat (NCT006670820) are
also under way. Further, Phase I trials for inhibition of PDGFRβ, FGFR and other tyrosine
kinases using Dovitinib in patients with advanced melanoma has shown promising results
[82]. Finally, rechallenging patients with selective BRAF inhibitors after a treatment-free in‐
terval provided clinical benefit to two patients who had previously progressed on MAPK in‐
hibitors [83]. Additional studies are required to determine the significance of rechallenging
patients after treatment interruption.
It has been suggested that a detailed catalogue of resistance mechanism in an individual’s
tumor should inform effective second line therapy [84]. This strategy may not prove suffi‐
cient, as it does not account for stromal-mediated resistance drivers, the heterogeneous na‐
ture of melanoma and the fact that melanoma tumors from a single patient may develop
multiple mechanisms of resistance. For instance, two independent vemurafenib-resistant no‐
dal metastases derived from a single patient, harboured distinct N-RAS activating mutations
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[29] and intra-tumoral heterogeneity has been observed in a progressing BRAF-mutant mel‐
anoma metastases from patients treated with BRAF inhibitors [85, 86].
Nevertheless, defining the mechanisms of RAF-inhibitor resistance is a critical step in under‐
standing the signalling pathways required to circumvent therapy. At present, up to 40% of
RAF-inhibitor resistant melanomas have undefined resistance drivers, and the role of
MAPK and PI3K signalling needs to be assessed in this subgroup. The fact that half of all
melanoma patients have wild type BRAF melanoma, further highlights the need for an inte‐
grated preclinical and clinical approach to guide rational design of effective initial and sec‐
ond-line treatment options.
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